Novel sequential treatment strategy for patients with muscle-invasive bladder cancer (MIBC): intravesical recombinant BCG, followed by neoadjuvant chemoimmunotherapy, radical cystectomy plus pelvic lymphadenectomy and adjuvant immunotherapy – protocol of a multicentre, single arm phase 2 trial (SAKK 06/19)

Introduction The combination of checkpoint inhibition and cisplatin-based chemotherapy is investigated in muscle invasive bladder cancer (MIBC) and results from phase 2 trials have been presented. Intravesical BCG has been used for non-MIBC (NMIBC) in patients with carcinoma in situ and high-grade T...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Richard Cathomas, Ulf Petrausch, Aurelius Omlin, Stefanie Hayoz, Martin Spahn, Martina Schneider, Cyrill A Rentsch, Sacha Rothschild
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	BMJ Publishing Group 2023-06-01
Sarja:	BMJ Open
Linkit:	https://bmjopen.bmj.com/content/13/6/e067634.full
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!